Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies

被引:19
作者
Tanaka-Harada, Yukie [1 ]
Kawakami, Manabu [2 ]
Oka, Yoshihiro [3 ]
Tsuboi, Akihiro [2 ]
Katagiri, Takamasa [1 ]
Elisseeva, Olga A. [1 ]
Nishida, Sumiyuki [2 ]
Shirakata, Toshiaki [2 ]
Hosen, Naoki [4 ]
Fujiki, Fumihiro [1 ]
Murao, Ayako [3 ]
Nakajima, Hiroko [4 ]
Oji, Yusuke [1 ]
Kanda, Yoshinobu [5 ]
Kawase, Ichiro [3 ]
Sugiyama, Haruo [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Canc Immunotherapy, Osaka, Japan
[3] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Osaka, Japan
[4] Osaka Univ, Grad Sch Med, Dept Canc Stem Cell Biol, Osaka, Japan
[5] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama, Japan
关键词
HUMORAL IMMUNE-RESPONSES; ANTIGEN SART-1; IN-VIVO; LYMPHOCYTES; PEPTIDE; PRODUCT; REPERTOIRE; INDUCTION; DISEASE; CLONES;
D O I
10.1111/j.1349-7006.2009.01453.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
WT1 (Wilms' tumor gene 1) protein is a potent pan-tumor-associated antigen (TAA) and WT1-specific cytotoxic T lymphocytes (WT1 tetramer(+) CD8(+) T cells) are spontaneously induced in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a single-cell level comparative analysis of T-cell receptor beta-chain variable region (TCR-BV) gene families of a total of 1242 spontaneously induced WT1 tetramer(+) CD8(+) T cells in HLA-A*2402(+) patients with AML or MDS and those in healthy donors (HDs). This is the first report of direct usage analysis of TCR-BV gene families of individual TAA-specific CD8(+) T cells at single-cell level. Usage analysis using single-cell RT-PCR of TCR-BV gene families of individual FACS-sorted WT1 tetramer(+) CD8(+) T cells showed for the first time (i) that BVs 5, 6, 20, and 27 were commonly biased in both HDs and patients; (ii) that BV4 was commonly biased in HDs and MDS patients; (iii) that BV19 was commonly biased in the patients; and (iv) that BVs 7 and 28, BVs 9 and 15, and BVs 12 and 29 were specifically biased in HDs, AML, and MDS patients, respectively. However, statistical analysis of similarity among HD, AML, and MDS of individual usage frequencies of 24 kinds of TCR-BV gene families indicated that the usage frequencies of TCR-BV gene families in AML and MDS patients reflect those in HDs. These findings represent a novel insight for a better understanding of WT1-specific immune response. (Cancer Sci 2010; 101: 594-600)
引用
收藏
页码:594 / 600
页数:7
相关论文
共 40 条
[21]   Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression [J].
Oka, Y ;
Tsuboi, A ;
Taguchi, T ;
Osaki, T ;
Kyo, T ;
Nakajima, H ;
Elisseeva, OA ;
Oji, Y ;
Kawakami, M ;
Ikegame, K ;
Hosen, N ;
Yoshihara, S ;
Wu, F ;
Fujiki, F ;
Murakami, M ;
Masuda, T ;
Nishida, S ;
Shirakata, T ;
Nakatsuka, S ;
Sasaki, A ;
Udaka, K ;
Dohy, H ;
Aozasa, K ;
Noguchi, S ;
Kawase, L ;
Sugiyama, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (38) :13885-13890
[22]   Cancer immunotherapy targeting Wilms' tumor gene WT1 product [J].
Oka, Y ;
Udaka, K ;
Tsuboi, A ;
Elisseeva, OA ;
Ogawa, H ;
Aozasa, K ;
Kishimoto, T ;
Sugiyama, H .
JOURNAL OF IMMUNOLOGY, 2000, 164 (04) :1873-1880
[23]  
Ostankovitch M, 1997, INT J CANCER, V72, P987, DOI 10.1002/(SICI)1097-0215(19970917)72:6<987::AID-IJC12>3.0.CO
[24]  
2-2
[25]   Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens:: Combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis [J].
Pilch, H ;
Höhn, H ;
Freitag, K ;
Neukirch, C ;
Necker, A ;
Haddad, P ;
Tanner, B ;
Knapstein, PG ;
Maeurer, AJ .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (02) :257-266
[26]  
Polz MF, 1998, APPL ENVIRON MICROB, V64, P3724
[27]   Avidity for antigen shapes clonal dominance in CD8+T cell populations specific for persistent DNA viruses [J].
Price, DA ;
Brenchley, JM ;
Ruff, LE ;
Betts, MR ;
Hill, BJ ;
Roederer, M ;
Koup, RA ;
Migueles, SA ;
Gostick, E ;
Wooldridge, L ;
Sewell, AK ;
Connors, M ;
Douek, DC .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (10) :1349-1361
[28]  
Roers A, 1998, EUR J IMMUNOL, V28, P2424
[29]  
Romero P, 1997, J IMMUNOL, V159, P2366
[30]  
SALVI S, 1995, CANCER RES, V55, P3374